Massivemarkets

Nasdaq: GENB · Listed Feb 27, 2026

Generate Biomedicines IPO

IPO price

$16.00

Generate Biomedicines (GENB) priced its IPO at $16.00 a share and has traded on Nasdaq since Feb 27, 2026.

GENB today$10.60-33.75%since IPO15-min delayed · as of 4:59:14 AM EST on Nov 19, 2026

See the GENB quote

First trading day · Feb 27, 2026

IPO price 16.00VWAP 13.35first trade 15.00-6.25% from the IPO pricelow 11.62$12.94volume · rising bars above the line, falling bars below489.33K12:504:00
IPO price
$16.00
inside the range of $15 to $17
First trade
$15.00
-6.25% from the IPO price
First-day last trade
$12.94
-19.13% from the IPO price, regular session
Raise
$400M
before the underwriters' option

These numbers are from the first trading day, Feb 27, 2026.

How GENB did against the market

GENB against the market, from its first trade at 12:50 ET to the last trade of the session.

GENB from its first trade
-13.73%
Against the market (QQQ)
-14.0 pts

GENB fell 13.7% from its first trade to the last trade of the session. That is 14.0 points worse than the market.

Same-day moves do not show that GENB caused them. The market is QQQ, the Nasdaq-100 ETF.

The debut race

GENB against other big listings, as the percent change from each stock's own IPO price.

The first 30 trading days. Each point is the last regular-session trade of a day.

+50%+100%+150%+200%+250%IPOday 1day 5day 10day 15day 20day 25day 30Figma '25 +69.64%Reddit '24 +40.32%CoreWeave '25 +28.42%Arm '23 -3.06%Klarna '25 -7.33%GENB -28.56%

The IPO scoreboard

GENB against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

GENB against other big IPOs: the money raised, and the return from each IPO price at the first trade, at the last trade of day 1, and on day 5 and day 30.
IPORaisedFirst tradeDay 1 closeDay 1 close, as a barDay 5Day 30
Generate Biomedicines '26$400M-6.25%-19.13%-22.12%-28.56%
Figma '25$1.22B+157.58%+252.42%+173.64%+69.64%
Circle '25$1.05B+122.58%+168.45%+278.18%+622.98%
Reddit '24$748M+38.24%+47.97%+69.90%+40.32%
Arm '23$5.23B+10.00%+23.76%+3.63%-3.06%
Klarna '25$1.37B+30.00%+16.14%+13.73%-7.33%
CoreWeave '25$1.5B-2.50%+0.02%+34.32%+28.42%

Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.

The offering

The Generate Biomedicines IPO offers 25M shares to raise $400M, before any underwriters' option.

$13$15$16$17$19
Expected price range
$15 to $17
IPO price
$16.00
Shares offered
25M
Money raised
$400M
Listing date
Feb 27, 2026
Exchange
Nasdaq
Security
Ordinary Shares

Money raised, against the largest IPOs

  • Alibaba '14$21.77B
  • Facebook '12$18.41B
  • Rivian '21$11.93B
  • Uber '19$8.1B
  • Arm '23$5.23B
  • Generate Biomedicines$400M

Where GENB ranks

Generate Biomedicines's market cap against the largest US-listed companies.

Market cap, against the largest US-listed companies

  • AAPL$5.12T
  • MSFT$3.77T
  • NVDA$3.65T
  • GOOGL$3.47T
  • AMZN$2.9T
  • TSM$1.88T
  • AVGO$1.69T
  • META$1.58T
  • TSLA$1.52T
  • BRK.B$1.22T
  • GENB$1.34B

GENB news

The latest news and headlines about Generate Biomedicines (GENB).

Filings and the company

What Generate Biomedicines has disclosed to the SEC, and the basic facts about the listing.

8-K filings

Material events that Generate Biomedicines discloses to the SEC on Form 8-K.

  • Quarterly earningsNov 12, 2026

    On November 12, 2026, Generate Biomedicines, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended September 30, 2026.

  • Draft copies of three posters submitted by Generate Biomedicines, Inc. include results of ongoing clinical trials sponsored by the Company, entitled: 'GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients'; 'SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma'; and 'GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.'

  • Charter amendmentMar 2, 2026

    The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware on March 2, 2026... to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company's stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.

About Generate Biomedicines

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Ticker
GENB
Exchange
Nasdaq
Market
stocks
Type
CS
Currency
USD
Industry
PHARMACEUTICAL PREPARATIONS
Listed
Feb 27, 2026
Security
Ordinary Shares
Company website

Frequently asked questions

What was the Generate Biomedicines IPO price?

$16.00 a share.

When did Generate Biomedicines go public?

Generate Biomedicines listed on Nasdaq on Feb 27, 2026 under the ticker GENB.

How much did the Generate Biomedicines IPO raise?

$400M, before any underwriters' option.

How did Generate Biomedicines open on its first day?

GENB first traded at $15.00, -6.25% from the IPO price of $16.00.

How did GENB close on its first day?

Its last regular-session trade was $12.94, -19.13% from the IPO price of $16.00.

What was the GENB first-day trading range?

$11.44 to $15.32 in the regular session.

How many GENB shares traded on the first day?

5.82M shares in the regular session.

How many shares did Generate Biomedicines sell in its IPO?

25M shares.

How did GENB do against the market on its first day?

GENB fell 13.7% from its first trade to the last trade of the session. That is 14.0 points worse than the market (QQQ, the Nasdaq-100 ETF).

What exchange is GENB listed on?

Generate Biomedicines lists on Nasdaq under the ticker GENB.

Build with Massive

Get the GENB data behind this page

The Massive endpoint behind each section of this page
What the page showsEndpoint
Offering terms and dates/vX/reference/ipos
Price/v3/snapshot
Chart, VWAP, and the market comparison/v2/aggs/ticker/GENB/range/5/minute
Market cap/v3/reference/tickers/GENB
News/v2/reference/news
Filings/vX/disclosures

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.